Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.18 USD | +1.11% | -1.73% | -5.02% |
Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.02% | 1.64B | C | ||
+0.89% | 12.8B | B+ | ||
-10.29% | 7.61B | B- | ||
+1.78% | 5.41B | B | ||
-1.16% | 4.51B | C | ||
+5.74% | 4.49B | C | ||
-50.70% | 3.29B | D+ | ||
+12.21% | 2.73B | - | - | |
-16.13% | 2.02B | B- | ||
-11.50% | 1.73B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.